AstraZeneca's Tagrisso 'backbone treatment' for EGFR-mutated lung cancer 12-Jun-2023 By Liza Laws AstraZeneca’s small molecule drug, Tagrisso (Osimertinib) achieved unprecedented survival in early-stage epidermal growth factor receptor mutated (EFGRm) lung cancer.
Urgent need for the continued development of targeted treatment for NSCLC after study 'shows potential' 05-Jun-2023 By Liza Laws There is an urgent need for more targeted treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although first-line treatment has shown potential in a clinical study.